AFP
TCRT icon

Ausdal Financial Partners’s Alaunos Therapeutics TCRT Stock Holding History

Ausdal Financial Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-23
Closed -$28K – 930
2015
Q4 		$28K Buy
+23
New +$38K 0.01% 618

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ausdal Financial Partners's TCRT Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 23 shares — an estimated $28K sold.

Ausdal Financial Partners first reported a position in TCRT in Q4 2015 and held it in 1 quarter. The position peaked at $28K in Q4 2015. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 23 Alaunos Therapeutics shares in Q1 2016, an estimated $28K.
  • Ausdal Financial Partners first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Alaunos Therapeutics position peaked at $28K in Q4 2015.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.